Bilateral mastectomy reduces BRCA-related cancer mortality

Share this content:
Bilateral Mastectomy Cuts Mortality for <i>BRCA</i>-Related CA
Bilateral Mastectomy Cuts Mortality for BRCA-Related CA

(HealthDay News) -- Women with BRCA-associated early-stage breast cancer who receive bilateral mastectomy are less likely to die from breast cancer than those who receive a unilateral mastectomy, according to research published Feb. 11 in BMJ.

Kelly Metcalfe, M.D., of the University of Toronto, and colleagues performed a retrospective analysis of data for 390 women, carriers of the BRCA1 or BRCA2 mutations, who underwent unilateral mastectomy or bilateral mastectomy (181 patients) as initial treatment for stage I or II breast cancer.

The researchers found that, at 20 years (median follow-up time, 14.3 years), the survival rate for women with hereditary breast cancer was 88 percent (95 percent confidence interval [CI], 83 to 93 percent) for those who had bilateral mastectomy and 66 percent (95 percent CI, 59 to 73 percent) for those who had unilateral mastectomy. According to multivariable analysis, women with hereditary breast cancer who received a mastectomy of the contralateral breast were 48 percent less likely to die from breast cancer (hazard ratio [HR], 0.52; 95 percent CI, 0.29 to 0.93; P = 0.03). According to propensity score-adjusted analysis of 79 matched pairs, bilateral mastectomy was not significantly associated with reduced risk of death from breast cancer (HR, 0.60; 95 percent CI, 0.34 to 1.06; P = 0.08).

"Given the worse prognosis of BRCA1/2 associated breast cancers, the absence of mammary tissue after a contralateral mastectomy should translate into a reduction of breast cancer related deaths," writes the author of an accompanying editorial. "Nevertheless, larger studies tackling this issue are needed."

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs